Overview
Location
United States, North Carolina, Durham
Employees
1-10
Phone
+30 2651 071157
Total raised
$4.9M
Funding Rounds 1
| Date | Series | Amount | Investors |
| Sign up to see | Sign up to see | Sign up to see | Sign up to see |
Mentions in press and media 8
| Date | Title | Description |
| Sign up to see | Sign up to see | Sign up to see |
| Jun 13, 2011 | AIDS drug company Trimeris to merge with Synageva | Synageva was founded in 2008. Its lead drug candidate is SBC-102, an enzyme replacement therapy for patients with lysosomal acid lipase deficiency, a rare genetic disease in which patients are born without the ability to produce the lysosom... |
| May 26, 2011 | AIDS drug company Trimeris gets $4.9M in settlement with Roche | But Trimeris objected to the way in which Roche calculated the cost of goods sold for Fuzeon, which affects the royalty that Trimeris receives. Last year, Roche told Trimeris that the change in royalty payments was in accordance with a clau... |
| Aug 8, 2007 | Personalized medicine takes a (tiny) step forward | (UPDATED: See below.) For at least a decade, biotech futurists have been predicting that the genomics revolution will lead to medical treatments tailored to the genetic quirks of individuals. And for at least as long, we’ve all been waiting... |
| Jul 19, 2007 | Venture capitalists turn drug developers | Calvert Holdings, a Cary, N.C., financial and healthcare conglomerate, has formed a new venture-capital fund that cuts out the middleman — in the case, a venture-financed biotech or pharma firm — by acquiring drug candidates and running the... |
| AIDS drug company Trimeris gets $4.9M in settlement with Roche | AIDS drug company Trimeris (NASDAQ:TRMS) is getting $4.9 million from partner Roche (OTC:RHBBY) to settle a royalties dispute regarding the AIDS drug Fuzeon. Durham, North Carolina-based Trimeris and Swiss pharmaceutical giant Roche have cl... | |
| AIDS drug company Trimeris to merge with Synageva | AIDS drug company Trimeris‘s (NASDAQ:TRMS) plan to merge with drug development company Synageva BioPharma would give Durham, North Carolina-based Trimeris the buyer it has been seeking and it would provide privately held Synageva a public l... | |
| AIDS drug firm TRMS to become GEVA in Trimeris/Synageva reverse merger | AIDS drug company Trimeris (NASDAQ:TRMS) this year vetted an initial list of more than 140 companies in all therapeutic areas and narrowed its business combination prospects to 14, then paired that list even further to five. That list inclu... |
Reviews 0
FAQ about Trimeris
How much funding has Trimeris raised?
Trimeris has raised $4.9M in total across 1 funding round.
What has the press written about Trimeris?
Parsers VC has collected 8 articles mentioning Trimeris, among them “AIDS drug company Trimeris to merge with Synageva” (Jun 13, 2011) and “AIDS drug company Trimeris gets $4.9M in settlement with Roche” (May 26, 2011).
Is Trimeris still active?
Trimeris is probably closed: its latest activity on Parsers VC dates from Jul 19, 2011.